Cancer, radiopharma & RDCs 2024-02-27
Market potential of radiopharma & RDCsRDCs are currently being developed for cancer. According to the WHO IARC, in 2022, the five most common cancers resulted in 19,956,054 new cases and 9,736,520 deaths. It is estimated that by 2050, the incidence of all cancers will reach 35.3 million. Consequentl
Read More